# A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

> **NCT04417517** · PHASE1 · TERMINATED · sponsor: **ALX Oncology Inc.** · enrollment: 65 (actual)

## Conditions studied

- Higher Risk Myelodysplastic Syndromes

## Interventions

- **DRUG:** evorpacept
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT04417517
- **Lead sponsor:** ALX Oncology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-02
- **Primary completion:** 2025-01-17
- **Final completion:** 2025-06-10
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** While intended to be a Phase 1/2 clinical study, the study did not proceed to Phase 2.
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417517, "A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04417517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*